Nonetheless, as MM is seemingly less responsive to immunotherapy than cutaneous melanoma, patients with resectable MM may need addition of anti-CTLA4 to anti-PD1 to derive clinical benefit. Here, CTLA4 is linked to cutaneous melanoma.